Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, we aim to deliver therapies designed to fit seamlessly into daily life.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q1 2026 · $94.1MThe company’s own SEC segment disclosure.
- Royalty$32.7M35%
- License And Service$23.5M25%
- Furoscix$15.5M16%
- Afrezza$15.3M16%
- V Go$3.1M3%
- Manufacturing Services$2.4M3%
- Other (1)$1.5M2%
MannKind Corporation (MNKD) reported revenue of $90M in Q1 2026 (quarter ended March 31, 2026), up 15% from the same quarter a year earlier. That came with a gross margin of 92% and net loss of $17M. For the full year FY2025, revenue was $349M (+22% year on year) and net income $5.9M. Its largest product in 2026-Q1 was Royalty at $33M, 35% of the disclosed total, just ahead of License And Service at 25%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.